Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2025
0mins
Source: Globenewswire
Emerging Growth Conference Announcement: The 78th Emerging Growth Conference is scheduled for January 15 & 16, 2025, featuring various companies across growth sectors presenting their innovative products and strategies to engage with the investment community.
Conference Details: The event includes keynote speakers from multiple companies, a virtual format for presentations, and opportunities for attendees to submit questions to the presenting companies.
Analyst Views on GOVX
Wall Street analysts forecast GOVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOVX is 12.00 USD with a low forecast of 10.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.880
Low
10.00
Averages
12.00
High
14.00
Current: 2.880
Low
10.00
Averages
12.00
High
14.00
About GOVX
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. It is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
